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preface to the second edition
The availability and use of medical abortion has increased rapidly since the 
publication of the first edition of this guidebook in 2004. We wrote the second 
edition of Providing Medical Abortion in Developing Countries: An Introductory 
Guidebook to incorporate important scientific developments and innovations in 
clinical practice. These changes have informed the emergence of protocols that 
can be used in a variety of low-resource settings worldwide. The new title Providing 
Medical Abortion in Low-Resource Settings reflects these broader applications. 
The guidebook follows the same chapter and topic sequence as the first edition. 
The second edition includes updated information on routes of misoprostol 
administration, infection and medical abortion, use of medical abortion for late 
first trimester abortion induction, telemedicine and medical abortion, professional 
and international clinical guidelines for use of mifepristone-misoprostol medical 
abortion, and a list of additional resources now available. 
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1i.  introduction
The term medical abortion refers to pregnancy termination with abortion-inducing 
medications in lieu of a surgical procedure.1 Although the idea of using medications 
to induce abortion has been around for centuries, evidence-based regimens for 
use in the first trimester of pregnancy only became a reality in the last 25 years. 
Mifepristone (commonly referred to as RU-486) was developed in France in the 
1970s and 80s by researchers investigating glucocorticoid receptors. The first 
clinical study of the drug as an abortifacient began in Geneva in 1981. In 1985, 
investigators reported that in combination with a prostaglandin analog (now, 
almost universally misoprostol) increased the efficacy of mifepristone. In 1988, 
France became the first country (outside of China) to license mifepristone for use 
in combination with a prostaglandin analog for early abortion. Since that time, the 
method has slowly spread around the globe, and millions of women have used the 
method worldwide. 
Mifepristone is now registered in over 40 countries. In 2005, mifepristone was 
included in the World Health Organization’s (WHO) Essential Medicines List. In 
recent years, several new mifepristone and prostaglandin analog (misoprostol) 
products have entered the market increasing the availability and reducing the cost of 
both drugs. New simplified regimens are making medical abortion more acceptable 
to women and providers. Together these developments are helping an increasing 
number of women access a non-surgical option for termination of pregnancy. 
Medical abortion has the potential to increase access to safe abortion services 
because it can be offered by providers in settings where surgical abortion may not 
be safe or widely available. 
The first edition of this guidebook (2004) grew out of a meeting held in Bellagio, 
Italy in July 1998, where a group of researchers, healthcare providers, women’s 
health advocates, donors, and representatives of ministries of health discussed 
the potential of medical abortion in the international arena. After much debate, the 
group came to consensus that a regimen of mifepristone followed by a suitable 
prostaglandin can feasibly be delivered in a manner that is safe, effective, and 
acceptable for women in developing countries.2 Harnessing the momentum gained 
from this initial meeting, a small group of medical abortion experts from around the 
world assembled in July 2000 to develop recommendations for use in low-resource 
2settings. The goal of this second meeting was to provide comprehensive, easy to 
understand guidelines for new providers and policymakers worldwide. 
In 2009, the guidebook was revised, reflecting recent scientific and programmatic 
developments in the use of mifepristone-misopostol for early abortion. The new 
title “Providing Medical Abortion in Low-Resource Settings” underscores how 
these developments have encouraged the creation of simplified medical abortion 
protocols relevant in low-resource settings worldwide.
How to use this guidebook
This guidebook is geared to providers and policy makers who are interested in 
learning about medical methods for safe termination of early pregnancy. The 
information in this guidebook is meant for readers with a basic knowledge of 
reproductive biology and women’s health services. The guidebook may also serve 
as an introduction to those with no prior knowledge about medical abortion. Topics 
mentioned more than once are cross-referenced. 
ii.  overview
A. What mifepristone is and how it works
Mifepristone is an antiprogestin licensed for pregnancy termination in many 
countries around the world. In some European countries, mifepristone is also 
licensed for cervical softening prior to first trimester abortions, cervical softening for 
second trimester abortion, and induction of labor following intra-uterine fetal death. 
It is currently under study for a number of other potential applications. Mifepristone 
blocks progesterone receptors, and, if taken in early pregnancy, the uterus can 
no longer sustain the growing embryo. Mifepristone also triggers an increase in 
endogenous prostaglandins and dilates the cervix, facilitating abortion.
When used alone, mifepristone has been shown to be from 60 to 80% effective 
in inducing abortions in pregnancies of less than 49 days since the last menstrual 
period (LMP). Because the drug makes the uterus more sensitive to the muscle 
contracting effects of prostaglandins, the combination of mifepristone with a 
prostaglandin analog increases the efficacy of the regimen. Initially, sulprostone 
(an injectable prostaglandin) and gemeprost (a vaginal suppository) were used 
with mifepristone in Europe. Sulprostone was associated with a number of 
cardiovascular incidents, including one fatal myocardial infarction, and its use 
was supplanted by misoprostol (an oral prostaglandin analog). Gemeprost is still 
used occasionally in the second trimester in the United Kingdom and Sweden. 
Worldwide, misoprostol is currently the favored prostaglandin for use with 
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•	 Efficacy when used with a prostaglandin for early medical abortion
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4mifepristone because of its safety, low cost, wide availability, stability at room 
temperature, and easy administration.3 Misoprostol may be administered orally, 
vaginally, buccally, or sublingually and is generally taken 24-48 hours after ingestion 
of mifepristone.
B. Efficacy
A successful medical abortion is defined as complete termination of pregnancy 
without the need for a surgical procedure. Mifepristone-misoprostol medical 
abortion for early first trimester pregnancies has a high success rate, generally 
around 95% (see Appendix A for success rates reported in clinical trials), although 
even higher in some service delivery systems (98.5% in the Planned Parenthood 
Federation of America).4,5 Failure, defined as recourse to a surgical procedure, 
may be the result of an ongoing pregnancy, incomplete expulsion, heavy bleeding, 
judgment of the provider that the medical process should be terminated surgically, 
or the request of the woman. Fewer than 5% of women expel the products of 
conception after mifepristone but before taking misoprostol.6 The majority of 
women expel within 24 hours of misoprostol administration but the process may 
take up to 2 weeks to complete. 
Factors that may affect efficacy:
•	 Gestational age of pregnancy: Medical abortion is less effective as gestational 
age increases. Regimens using buccal, sublingual and vaginal misoprostol are 
highly effective at gestational ages up to nine weeks’ LMP. Oral misoprostol is 
also highly effective at gestational ages up to eight weeks’ LMP but declines 
slightly at later gestational ages (see Appendix A). The method remains effective 
in the late first trimester and many different regimens are equally feasible (see 
Chapter VII). 
•	 Regimen: Regimens for mifepristone-misoprostol medical abortion vary in 
terms of misoprostol dose, timing of the doses, and misoprostol route of 
administration. Although the efficacy of regimens does not appear to vary 
widely at gestational ages less than eight weeks there is evidence that regimen 
variations may have an effect on efficacy in gestations greater than eight weeks’ 
LMP (see Chapter IV, Section A) but provider practices are probably more 
important than what regimen is chosen. 
•	 Provider: Success rates for providers using the same regimen often vary 
considerably. A provider may decide to complete the abortion surgically for 
convenience when not medically necessary or may mistakenly believe the 
abortion was not complete and intervene surgically. Factors that may lead 
a provider to intervene unnecessarily include incorrect clinical judgment, 
provider impatience, and inexperience with the method. As providers become 
more comfortable with the method, they tend to achieve higher success rates 
because they are willing to wait longer for the medical abortion to complete.7,8 
Additionally, as staff gain confidence and experience, they may be better able 
to provide support and counseling to women who otherwise might request 
surgical intervention despite an underlying wish to abort without surgery. 
•	 Visit schedule: Protocols that allow more time between drug administration and 
the follow-up visit and/or allow for multiple follow-up visits may have higher 
success rates since some women’s abortions are not complete for several days 
or even several weeks after use of the drugs. Many women want to know as 
soon as possible if the abortion is finished, so early follow-up consultations 
for women who want to confirm that the abortion is complete may increase 
satisfaction levels. On the other hand, excessive follow up may lead to needless 
interventions, inflating the failure rate.
C. Safety 
Early medical abortion with mifepristone and misoprostol is extremely safe. There 
is less risk associated with properly used modern methods of abortion, including 
medical abortion, than with the continuation of pregnancy.4,9,10,11,12 Millions of 
women worldwide have safely and successfully used mifepristone for early medical 
abortion. Neither drug has been associated with long term effects on women’s 
health.13 
Frequently cited safety concerns:
•	 Excessive bleeding: Bleeding can best be managed if women are counseled on 
what to expect and when to seek treatment if bleeding becomes very heavy or 
persists for a long time (see Chapter IV, Section C). Bleeding excessive enough 
to warrant a blood transfusion is extremely rare; less than one woman per 2,000 
who use medical abortion experience it.4,14,15
5
6•	 Ectopic pregnancy: Medical abortion with mifepristone neither exacerbates nor 
ends an ectopic pregnancy. Careful evaluation before treatment and careful 
monitoring for symptoms after treatment can help to identify women with 
ectopic pregnancies so that they may be referred for appropriate treatment. 
•	 Teratogenic effects: A very small percentage of pregnancies may continue after 
administration of mifepristone-misoprostol. In such cases, if a woman changes 
her mind about her abortion, or in the rare instance that the clinician fails to 
diagnose an ongoing pregnancy at a follow-up visit, the pregnancy may continue 
to term. Although it is possible that either drug could have teratogenic effects 
on the fetus, there is no evidence that mifepristone causes deformities. Limb 
defects and Mobius syndrome have been reported after misoprostol use but 
prospective data show no association with birth defects.16 Overall, data on 
misoprostol suggest a possible association between birth defects and in utero 
exposure to misoprostol at a narrow sensitive window very early in gestation. 
While the relative risk of malformations appears real, epidemiological studies 
indicated that the absolute risk is low (less than 10 malformations per 1,000 live 
births exposed to misoprostol in utero).17,18 During counseling, it is important to 
emphasize to the woman the need for follow up and completion of the abortion 
if the pregnancy is ongoing. All women should be informed of the possibility 
of birth defects if they elect to continue a pregnancy to term after exposure to 
misoprostol. 
•	 Infection: Serious infection following medical abortion (defined as an infection 
requiring intravenous (IV) antibiotics and hospitalization) is rare.19 In the United 
States, where there is a well-functioning reporting system for adverse events 
following early medical abortion, the frequency of reported infections is about 2 
per 1,000 uses.20 Fatal infection associated with C. sordellii and C. perfringens has 
been reported, however, this phenomenom is extremely rare, occurring in less 
than 0.5 per 100,000 uses.21,22 Overwhelmingly, infections reported following 
medical abortion are not serious and are treated with a single course of oral 
antibiotics in an outpatient setting.
•	 Fertility: Medical abortion with mifepristone and misoprostol has no effect on a 
woman’s fertility.13 
D. Acceptability
Overall, studies have shown that medical abortion is very acceptable to both women 
and providers worldwide. For example, studies conducted in China, Cuba, India, 
Vietnam, Nepal, South Africa, Turkey and Tunisia found that over 90% of women 
were “satisfied” or “very satisfied” with their medical abortions.14,23,24,25,26,27,28,29 
Research from France, Scotland, and Sweden indicates that 60-70% of eligible 
women opt for medical methods of abortion if given a choice.30,31 In one study 
that queried women who had experienced both medical and surgical abortion, the 
majority preferred medical abortion to surgical abortion.32 It is important to note 
that a woman’s view of her abortion experience is often linked to the context in 
which the abortion is provided. 
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Medical abortion Surgical abortion
Advantages •	 Avoids surgery, anesthesia
•	 More natural, like menses
•	 Less painful to some women
•	 Easier emotionally for some 
women
•	 Can be provided by mid-level staff
•	 Woman can be more in control, 
involved
•	 Quicker
•	 More certain
•	 Less painful to some women
•	 Easier emotionally for some 
women
•	 Can be provided by mid-level 
staff in some settings
•	 Provider controlled
•	 Woman can be less involved
Disadvantages •	 Bleeding, cramping, nausea 
(actual or feared)
•	 Waiting, uncertainty
•	 Depending on protocol, more  
or longer clinic visits
•	 Cost
•	 Invasive 
•	 Small risk of uterine or 
cervical injury 
•	 Risk of infection
•	 Loss of privacy, autonomy
Table 2.1  Advantages and disadvantages of early abortion methods as  
 cited by women and providers33
8Summary points 
•	 The success rate of mifepristone and misoprostol medical 
abortions early in the first trimester up to 9 weeks’ LMP, is high, 
generally around 95%.
•	 Mifepristone has been used safely, effectively, and with high 
acceptability by millions of women around the world since 1988.
9iii. deciding to use medical abortion
A. Who can use medical abortion?
Most women with early pregnancies are able to choose mifepristone-misoprostol 
medical abortion. Very few women are excluded by labeling instructions in most 
countries.
Mifepristone contraindications:
•	 Suspected ectopic pregnancy or undiagnosed adnexal mass
•	 Chronic adrenal failure
•	 Concurrent long-term corticosteroid therapy
•	 History of allergy to mifepristone
•	 Hemorrhagic disorders or concurrent anticoagulant therapy (i.e. blood 
thinner medications)
•	 Inherited porphyrias (rare genetic blood diseases)
If an IUD is in place, it must be removed before medication is administered.
Chapter themes 
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Misoprostol contraindications: 
•	 History of allergy to prostaglandins, including misoprostol
Previously, medical abortion was advised against for women over 35 who also 
smoked more than 10 cigarettes per day. This exclusion criterion was later deter-
mined to be unnecessary after misoprostol replaced sulprostrone as the prosta-
glandin component of the regimen. Despite contraindications for use of some 
prostaglandins in women with asthma, medical abortion with mifepristone and 
misoprostol is not contraindicated for use in asthmatic women. In fact, unlike some 
prostaglandins, misoprostol relaxes the smooth muscles of the tracheo-bronchial 
tree, and so is not known to have adverse effects in asthmatic women.
Other conditions to consider:
•	 Severe anemia: Although women using medical abortion experience more 
prolonged bleeding than women having a surgical abortion, the total amount of 
blood loss and decrease in hemoglobin levels is typically modest for both meth-
ods. Anemia is not a contraindication for the method, but all women with severe 
anemia should initiate treatment for anemia as soon as it is diagnosed. 
•	 Breastfeeding: There is no evidence that mifepristone or the prostaglandins 
used for medical abortion are harmful to nursing infants. Given that the doses 
are few and fairly rapidly metabolized, it is unlikely these drugs would be found 
in large quantities in breast milk. However, most drugs in women’s blood do 
get into breast milk in small amounts. For this reason, women are sometimes 
advised to discard the breast milk produced for four to six hours after ingestion 
of each dose of misoprostol.34,35 
•	 Access to emergency back-up care: Although severe complications following 
medical abortion requiring emergency treatment or blood transfusions are rare, 
women should have adequate access to emergency back-up facilities during the 
abortion process.
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B. Gestational age dating for determining eligibility
The following tools can be used to calculate the gestational duration of a woman’s 
pregnancy.36,37,38 
•	 Last menstrual period: Studies have shown that almost all women are able to 
date their pregnancies reliably (i.e. within +/- 2 weeks of provider assessment 
using ultrasound) by calculating from the first day of their last menstrual 
period.39,40 
•	 Physical Exam: Experienced providers can assess gestational age by conducting 
a physical exam to estimate the size of the woman’s uterus. Special care  
should be taken with obese women because it may be difficult to conduct an 
accurate exam. 
•	 Ultrasonography: Ultrasound, as recorded and interpreted by an experienced 
sonographer, is a useful tool to date a woman’s pregnancy but other methods 
of dating pregnancies are also acceptable. If a provider suspects an ectopic or 
multiple pregnancy, ultrasound may help to confirm the diagnosis.
Precise dating of pregnancy is not needed for medical abortion. The estimate has to 
rule out pregnancies beyond 9 weeks mostly for service delivery and administrative 
reasons. Even after 9 weeks, the method still has a high probability of success  
(See Chapter VII). 
Additional factors to consider when determining gestational age limits:
•	 Legal and programmatic restrictions as applicable 
•	 Medical abortion drug regimen used and its efficacy at later gestational ages
•	 Women’s desire to have a medical abortion 
•	 Provider experience and comfort with the method
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Medical abortion and off-label use
 
In countries where mifepristone is licensed for use in medical abortion, the 
license will specify the regimen and gestational age limit for which the drug 
can be marketed. Yet, in many countries, licensed medicines can also be used 
in ways and for indications that are not included in the original registration. 
This is called “off-label use.” According to the United States Food and Drug 
Administration (FDA), “Good medical practice and the best interests of the 
patient require that physicians use legally available drugs, biologics and devices 
according to their best knowledge and judgment. If physicians use a product 
for an indication not in the approved labeling, they have the responsibility to 
be well informed about the product, to base its use on firm scientific rationale 
and on sound medical evidence, and to maintain records of the product’s 
use and effects.” Early mifepristone registrations specified the use of 600 
mg mifepristone and limited use of the method up to seven weeks gestation 
(49 days’ LMP). Later evidence demonstrated that a reduced dose of 200 
mg mifepristone was as effective (and less costly) up to 63 days’ LMP when 
combined with vaginal, buccal, or sublingual doses of misoprostol. Today,  
most protocols in the United States clinics and other countries provide for  
use off-label to 63 days’ LMP with a single 200 mg dose of mifepristone. 
Summary points 
•	 Most women can use mifepristone for early medical abortion.
•	 Early mifepristone misoprostol protocols were cautious; the safety and 
efficacy results of numerous clinical trials have enabled more women at 
later gestational duration access to the method.
•	 There is no evidence to show that mifepristone stops working or becomes 
dangerous at a certain gestational age; it appears to be more effective for 
earlier pregnancies.
•	 The gestational age of most pregnancies can be assessed by menstrual 
history and physical exam.
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iv.  medical abortion protocols with mifepristone and
  misoprostol
A. Dose, route, and timing of administration
Although the registered regimen is similar in most countries, local standards 
of care have introduced variants into many medical systems. Each of these 
regimens appears to be highly effective. Variations of the dose, timing, and route of 
administration and the evidence for these are discussed below.
Dose
•	 Mifepristone dose: A low dose of mifepristone (200 mg) has proven to be as 
effective as the originally used 600 mg dose and can greatly reduce costs.41,42,43,44
 
•	 Misoprostol dose: Most recommended medical abortion regimens use 400-
800 mcg misoprostol. Doses of 800 mcg vaginally and buccally (in the cheek) 
have been shown to be highly effective up to 63 days’ LMP. When administered 
sublingually (under the tongue) or buccally, even 400 mcg doses have been 
shown to be highly effective up to 9 weeks’ LMP (See Appendix A). Higher 
doses of prostaglandin may result in slightly higher success rates and/or shorter 
mean time to expulsion, but they are also linked to increased side effects. Some 
providers believe that repeat dosing of misoprostol for women who do not expel 
the products of conception in the first 24 hours or have incomplete abortions or 
heavy bleeding improves success rates. Studies in which participants repeat the 
Chapter themes 
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•	 Side effects and complications
•	 Follow up
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misoprostol dose following mifepristone tend to have higher efficacy rates than 
do studies in which women were given a single dose of prostaglandin, but the 
results are inconclusive.45,46
Route of administration
•	 Mifepristone: Mifepristone is administered orally. There is no evidence to 
suggest that alternative routes of administration may be more effective or 
convenient.
•	 Misoprostol: Studies have examined oral, vaginal, buccal, and sublingual 
administration of misoprostol for medical abortion. For buccal and sublingual 
administration, women are generally advised to hold the pills in their cheeks 
or under their tongue for 20-30 minutes and then swallow any remaining 
fragments. Buccal, sublingual, and vaginal administration of misoprostol have 
been shown to be highly effective up to 9 weeks’ LMP.47,48,49,50,51,52,53 Methods of 
delayed swallowing, such as buccal and sublingual administration, offer a safe 
and effective alternative at later gestational ages and may avoid the discomfort 
and distaste associated with vaginal administration. There may also be a 
difference in side effects by route of administration, but these findings may be 
confounded by the effect of different dosing schemes. 
Timing
•	 Gestational age: Mifepristone-misoprostol medical abortion appears to be 
most effective in early pregnancy. As gestational age increases, efficacy tends to 
decrease, although this decline is small and gradual.
•	 Timing of misoprostol administration: Most recommended medical abortion 
regimens require women to administer the misoprostol 24-48 hours after 
mifepristone. Studies demonstrate that the method is also successful when 
misoprostol is taken between 12-72 hours after mifepristone.54,55 Regimens 
employing shorter intervals (i.e. less than 12 hours) between mifepristone 
and misoprostol or simultaneous administration appear to be slightly less 
effective.56,57,58 Expanding the range of time in which misoprostol may be taken 
could increase the flexibility of this regimen, making it more accommodating for 
women’s and clinic’s schedules.
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B. Schedule of clinic visits
Most medical abortions in the United States and elsewhere require just two visits 
(see Figure 4.1). The approved regimen used in the United States specifies that 
a woman make three clinic visits: one to swallow the mifepristone, a second 
(1-3 days after mifepristone ingestion) to swallow the misoprostol, and a third 
(approximately 2 weeks later) to confirm that the abortion is complete. Yet, several 
studies have tested the safety and efficacy of home administration of misoprostol 
thereby reducing the number of clinic visits.23-25,27-29,59-62 Most women find this option 
preferable, and providers may find it easier and more feasible for service delivery. 
Home administration of misoprostol has become the standard of care in the United 
States, where over one million women have used the method in this way,20 and 
many other countries have also adopted this option. 
Most recommended medical abortion regimens require women to take mifepristone 
in the clinic. Yet, there are no data to substantiate the medical necessity of taking 
mifepristone, which has few to no side-effects for most women, under direct 
medical supervision. Data on home use of mifepristone are scant. One recent 
descriptive study of home use of both mifepristone and misoprostol by women 
who acquired the pills from the Women on the Web website and self-administered 
the tablets reported a success rate similar to those reported for other outpatient 
settings (93.2%).63
In addition, researchers are exploring how the follow-up visit could be omitted, or 
handled in ways other than through a personal appearance at a clinic. Potential 
alternatives include a self-administered patient assessment and low-sensitivity 
pregnancy test.64 To date, however, an effective pregnancy test is not commercially 
available, and further research is required to identify appropriate diagnostic tools for 
women.65
The following are potential scenarios in which the number of visits would increase: 
•	 A woman presents to a clinic with an unwanted pregnancy and after being given 
information about surgical and medical abortion, requests additional time 
before selecting a method.
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If abortion is complete 
Treatment complete 
If abortion is NOT complete
Schedule follow-up visit or  
surgical intervention
Figure 4.1 Typical series of medical abortion clinic visits 
clinic visit
•	 Counseling: Decision to have abortion, 
abortion methods available
•	 Medical evaluation
Women with no contraindications and selecting 
medical abortion: 
•	 Receive counseling about what to expect during 
the medical abortion process
•	 Administer mifepristone
•	 Choose where to administer misoprostol
•	 Receive counseling on how to administer 
misoprostol
•	 Receive counseling on contraceptive methods
clinic visit
Determine if abortion is complete
additional 
clinic visits
Woman may 
require more 
time before 
selecting 
abortion and/or 
method
Woman may  
require follow-up 
visit 
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•	 A woman returns for her two-week follow-up visit and learns that, though her 
pregnancy is not ongoing, her abortion is not complete. The decision is made 
to either administer additional doses of misoprostol or simply wait to see if the 
abortion completes without further intervention. In either case, an additional 
follow-up visit would be recommended. 
C. Managing side effects and complications
Most of the side effects associated with medical abortion are well-known and easy 
to manage. In the clinic, the person attending the woman (such as counseling staff, 
nurse, midwife, or a trained support person) should be able to describe possible 
side effects and their management and to address women’s concerns. In rare 
instances, a physician may be needed to manage side effects. 
The two most common intended effects are the pain (associated with uterine 
cramping) and vaginal bleeding. These symptoms are expected, as they are part of 
the abortion process and not really “side effects.” Women can be given either pain 
medication tablets or a prescription for pain medication before leaving the clinic. 
They should also be instructed to seek additional care (either at the clinic or an 
emergency facility) if they are bleeding excessively (see definition below) or have a 
persistent fever. See Table 4.1 for a description of common effects, complications, 
and suggestions for management of these problems.
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Reports of pain and perceived need for analgesia 
vary greatly from culture to culture, clinic to clinic, 
and person to person. For instance, in places 
where surgical terminations are performed with 
no anesthesia, medical abortion is often rated as 
almost painless. Most women report at least some 
pain, however, and roughly half perceive a need 
for analgesia. Pain rarely indicates the need for a 
surgical intervention and tends to improve rapidly 
once the expulsion takes place.
•	 Hot water bottle or heating pad
•	 Sitting or lying comfortably
•	 Support of friends/family
•	 Soothing music, television, tea (where 
available)
•	 Paracetamol/acetaminophen
•	 Non-steroidal anti-inflammatory drugs 
(NSAIDs) such as ibuprofen
•	 Weak opioids such as codeine (and 
one of the above)
All women who experience a successful medical 
abortion will experience vaginal bleeding. Bleeding 
is likely to be more abundant and prolonged 
than normal menstruation but typically does 
not adversely affect hemoglobin levels. The total 
amount of blood loss is related to gestational age.66 
Bleeding is often heaviest three to six hours after 
the prostaglandin administration and usually lasts 
about a week but may last as long as a month for 
some women.
•	 Set reasonable expectations about 
bleeding during pre-abortion 
counseling
•	 Give clear instructions about how to 
decide if bleeding is excessive and 
where to go for additional care
Excessive or prolonged bleeding causing a clinically 
significant change in hemoglobin concentration 
is uncommon.49,67,68 Approximately 1% of women 
will require uterine evacuation for hemostatic 
control. The need for transfusion is even rarer 
(0.1% to 0.2%). There are no reports in the medical 
literature of hysterectomy for hemostasis after 
medical abortion.
While it is important to explain to the woman that 
most medical abortions take place without incident, 
it is equally important to encourage the woman 
to call her provider if she experiences excessively 
heavy bleeding. Establishing a sanitary pad count 
(or local equivalent) will help make bleeding 
measurement concrete. In the United States, for 
instance, women are told that if they soak more 
than two super-size sanitary pads per hour for two 
consecutive hours they should call a provider.
•	 If there is evidence of hemodynamic 
compromise, intravenous fluids 
should be administered
•	 If bleeding is particularly profuse or 
prolonged, surgical intervention may 
be required
•	 Transfusion should be provided only if 
clearly medically required
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Table 4.1 Treatment and management of side effects and complications  
 (continued)
Fe
ve
r/
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Misoprostol can sometimes cause temperature 
elevations. These temperature elevations do not 
usually last more than two hours or so. Although 
uterine/pelvic infections are rare in medical 
abortion, a fever that persists over several days or 
that starts days after prostaglandin administration 
could signal an infection. 
•	 Provide anti-pyretics and reassurance
•	 If fever persists for more than four 
hours or develops more than a day 
after misoprostol administration, 
the woman should be instructed to 
contact the clinic
Nausea has been documented in approximately 
half of all women undergoing medical abortion 
and vomiting may occur in fewer than a third. 
These symptoms are usually related to pregnancy 
and administration of the medical abortifacients. 
They may appear or increase in intensity after 
mifepristone administration and usually decline 
hours after misoprostol intake. 
•	 Reassure women that nausea and 
vomiting are commonly associated 
with pregnancy and are also a possible 
side effect of the medication
•	 Provide women with anti-nausea or 
anti-emetic medication for severe 
symptoms if the drugs are available
Transient diarrhea appears in fewer than a quarter 
of all women after misoprostol administration. 
Since the diarrhea is almost always short-lived, 
treatment is rarely necessary.
•	 Reassure the woman that diarrhea 
is sometimes associated with 
misoprostol and usually passes rapidly
These symptoms have been documented in fewer 
than a quarter of all women. They are usually 
self-limited, resolve spontaneously, and are best 
managed symptomatically. 
•	 Provide reassurance and analgesia as 
needed
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Description Management
In
fe
ct
io
n
Serious infection following medical abortion 
(defined as an infection requiring IV antibiotics 
and hospitalization) is rare.19 In the United States, 
where there is a well-functioning reporting system 
for adverse events following early medical abortion, 
the frequency of reported infections is about 2 
per 1,000 uses.20 Fatal infection associated with 
C. sordellii and C. perfringens has been reported, 
however, this phenomenom is extremely rare, 
occurring in less than 0.5 per 100,000 uses.21 22 
Overwhelmingly, infections reported following 
medical abortion are not serious and are treated 
with a single course of oral antibiotics in an 
outpatient setting.
•	 If infection is suspected (see fever) 
the woman should be evaluated
•	 If there is evidence of endometritis 
and the abortion is incomplete, a 
surgical abortion should be performed 
and antibiotics provided
•	 Any severe infection could require 
hospitalization and parenteral 
antibiotics
•	 Antibiotic administration (either 
prophylactically or with screen and 
treat protocols) is used in some 
settings, including the United 
Kingdom and Sweden and clinics of 
the Planned Parenthood Federation of 
America. However, routine antibiotic 
use may not be feasible in all settings, 
for all women, and is not without its 
own risks of side effects and serious 
adverse events, such as serious and 
fatal allergic reactions. Neither the 
United States FDA nor the WHO 
recommend routine antibiotics for 
medical abortion procedures.
Table 4.1 (continued)
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D. Follow up
The following tools can be used to evaluate whether or not the abortion was a 
success.36 
•	 Physical exam: Woman’s report of symptoms of abortion (see Chapter IV, 
Section C for information on pain/bleeding patterns) with physical examination 
demonstrating return of uterus to pre-pregnant size. 
•	 Ultrasonography: Ultrasound examination can be a useful tool for evaluation 
of success if the provider has expertise in the technique. It is important to 
differentiate between blood clots/debris, true incomplete abortion and an 
ongoing pregnancy.69 Evacuation of the uterus in a clinically well woman is 
not indicated even if some debris can be seen on ultrasound exam. As with 
spontaneous abortion, expectant management is often sufficient for all but 
ongoing pregnancies. 
Persistent gestational sac
Even after fetal demise, a non-viable gestational sac may be retained in 
the uterus. If the woman has no symptoms of infection, no worrisome 
bleeding, and wishes to wait for expulsion, she may do so. Additional 
doses of misoprostol may induce uterine activity to expel the pregnancy 
tissue.70 
Management:
•	 Consider administration of additional doses of misoprostol
•	 Provide reassurance to the woman: If there are no signs of clinical 
danger (e.g. fever, heavy bleeding) it is safe to wait for expulsion or  
to take another course of misoprostol. 
•	 Research on the optimal dose of misoprostol for this indication is 
under investigation.70 
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Serum b-hCG decline after medical abortion 
The serum concentration of b-hCG (human chorionic gonadratropin) rises 
exponentially during the first six weeks of pregnancy, with reported doubling 
times of approximately 1.3 to 2 days.36 Although mean serum levels have been 
shown to be highly correlated with gestational age during early pregnancy, a wide 
range of values is compatible with normal progression of pregnancy at early 
gestational ages. Only readings outside a wide range indicate a problem, as do 
serial readings that do not change appropriately. 
A single hCG reading cannot be used to date a pregnancy with precision. To 
document a change in hCG, a comparison of sequential serum samples is 
necessary. A decline in serum hCG levels can indicate that the pregnancy has 
ended. Increase of hCG levels can indicate ongoing pregnancy. If hCG levels have 
declined 50% in 24 hours, the pregnancy is likely to have ended.71,72 In women 
with complete medical abortion, hCG serum concentration should be below 
1,000 IU/L two weeks after mifepristone administration.73 Time to reach very low 
levels (below 50 IU/L) is directly related to the initial hCG level.74
Summary points:
•	 Many mifepristone-misoprostol regimens work well for early first trimester 
pregnancy termination. 
•	 The vast majority of women make two clinic visits during their medical 
abortion procedures. However, the number of visits a woman makes to 
her health care provider can range from one (one for medical evaluation, 
counseling and mifepristone administration) to four or more, depending on 
individual circumstances and the protocol followed. 
•	 Primary effects (i.e. pain and bleeding) and side effects are expected and well 
tolerated by women.
•	 It is important to confirm that each medical abortion is complete. However, a 
clinic visit may not be required to confirm whether the procedure is complete.
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v.  counseling and information provision
Information is a crucial component of medical abortion.75,76 Counseling provides the 
opportunity to inform women about what to expect and to ensure that women know 
the warning signs of the need for additional help. Clinical experience has shown that 
medical abortion counseling may be closely related to the efficacy and acceptability 
of the method. If women are properly informed about what to expect after taking 
the drugs, they are better prepared for their experiences and less likely to request a 
medically unnecessary surgical termination to end the process. In addition, women 
who are more confident about and comfortable with the method may find it more 
satisfactory. 
If providers and women are less familiar with medical abortion methods, counsel-
ing may take longer than prior to surgical abortions. As providers gain more experi-
ence, the amount of time required for counseling tends to decrease. For a detailed 
counseling checklist, please see Appendix B.
A. Choosing a method
If both medical and surgical abortion methods are available, a brief description of 
both of these options should be given to women. Below is a sample of a description 
of medical abortion:
Medical abortion is a method of abortion that uses pills to end a pregnancy. 
Two different medications are needed for a medical abortion. To use this 
Chapter themes 
•	 Choosing a method
•	 Screening for suitability
•	 Preparing the woman for what to expect
•	 Contraception after the abortion
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method, women take the first kind of pill, called mifepristone, to start 
the abortion. Later, they take a second set of pills, called misoprostol, to 
complete the treatment, at home or in the clinic. Following the second set 
of pills, women may experience cramping, bleeding, nausea, vomiting, and 
diarrhea. Most of these side effects generally go away after a few hours, but 
bleeding similar to a heavy period can continue for a week or longer. Studies 
have found this regimen effective about 95% of the time and very acceptable 
to most women.
It is important to provide complete, accurate and unbiased information to enable 
each woman to select the most appropriate method for herself. Women should not 
be coerced into selecting either a medical or surgical abortion. Providers should 
take time to inform the woman that if the medical abortion fails, she may need to 
have a surgical intervention to complete the procedure. Issues such as personal 
beliefs, privacy preferences and social context should be considered.
B. Screening for suitability
Each woman should be screened to assess her eligibility for medical abortion. From 
the medical standpoint, it is important to determine whether or not the method is 
appropriate for the woman, including that a pregnancy is not greater than 9 weeks’ 
LMP and if the woman has any known contraindications. In addition, it is useful for 
the provider to discuss the various options available to each woman so the woman 
can determine if medical termination fits well with her needs and expectations. For 
example, each user needs to be comfortable with the waiting time to completion. 
The following list highlights areas that should be incorporated into standard 
screening for medical abortion.
•	 Medical history (see Chapter III, Section A)
•	 Personal characteristics and preferences
•	 Social circumstances: family/partner support, job and household responsibilities
•	 Access to adequate back-up facilities
•	 Ability to return to clinic for a follow-up visit as or if necessary
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C. Preparing the woman for what to expect
Counseling allows the provider to help women develop realistic expectations about 
the abortion. To assist with this process, the following issues should be discussed:
•	 Mifepristone and misoprostol: Explain what they are, how they work, and how 
they should be taken. 
•	 Misoprostol administration: Explain how women should administer the 
misoprostol tablets. For example, for buccal (and sublingual) administration, 
women are advised to place the misoprostol tablets in the cheek cavity for the 
buccal route (or under the tongue for the sublingual route) for 20-30 minutes 
and then swallow the pill remnants. 
•	 Success rate: Explain that between 2 - 8% of women will require a surgical 
intervention. If the drugs fail, the woman should be prepared to complete the 
abortion surgically. 
•	 Understanding of the method: Rumors or misconceptions about the method 
should be dispelled, and all of the woman’s questions or concerns should be 
thoroughly reviewed.
•	 Expectations about primary and secondary effects: Discuss the amount of pain, 
bleeding and side effects that are commonly experienced. 
 
•	 Products of conception: Women should be informed that it is possible, though 
not likely, that they will see the products of conception. Some clinics find it 
useful to show women pictures of expelled products of conception at different 
gestational ages to enable women to have a realistic idea of what they  
might see.
•	 Possible complications: Women should be given a detailed description of 
possible complications and how they can be managed (see Chapter IV,  
Section C). In addition, if feasible within the local context, providers may want 
to give women a telephone number to call if they have any questions  
or concerns. 
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•	 Follow-up care: Although the woman may believe that her abortion is complete 
(i.e. if she believes she has seen the expulsion or bleeding has ceased), 
best current clinical advice is that each woman should return for her follow 
up to confirm that her abortion is complete. Future protocols may develop 
mechanisms by which a woman can assess her abortion status on her own, 
without having to make an additional clinic visit for this purpose.64 Low-
sensitivity pregnancy tests and self-administered questionnaires may help 
women and providers assess whether additional post-medical abortion care is 
required.
•	 Cost: In places where abortion services must be covered by the woman, the 
costs of each abortion method should be discussed.
•	 Informed consent: Depending on local regulations and practices, women 
may be required to sign a consent form. Informed consent should include 
an explanation of the process, a statement indicating that risks, benefits, 
complications and potential side effects have been fully explained and that 
the woman has had the opportunity to ask questions and received satisfactory 
answers. The consent form should also indicate that the woman has received 
detailed information about the procedures for emergency care, if needed. A 
sample informed consent form is included as Appendix C.
Best features  Worst features
•	 No surgery and/or injections and/or 
anesthesia
•	 Non-invasive
•	 Natural, like menses or miscarriage
•	 Less pain, cramping
•	 Easier emotionally, less frightening or 
traumatic
•	 Easier, simpler, faster
•	 Pain, cramping (feared or actual)
•	 Waiting, uncertainty, fear of unknown
•	 Nausea, vomiting, diarrhea (feared or 
experienced)
•	 Amount of bleeding 
•	 Fear of failure, true failure
•	 Takes too long
Best and worst features of medical abortion as reported by women 
participating in clinical studies13,23-29
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D. Contraception after the abortion
Contraception should be discussed with every woman. All women should be 
reminded that fertility returns quickly following early first trimester abortion. For 
this reason it is critical that women understand the subsequent risk of pregnancy. 
Information about contraception should be provided at the first clinic visit. Women 
having medical abortions can begin using oral contraceptives, injectables and 
implants the day of misoprostol administration. Condoms, contraceptive jellies 
and foams, the cervical cap, and the diaphragm should be used with the first sexual 
relations. It is best for women requesting intrauterine devices to wait until their 
abortions are complete before insertion. An appropriate contraceptive method will 
depend on local availability and the needs and preferences of each woman. 
Summary points:
•	 Providing women with complete information is critical to ensure 
success, safety, and acceptability.
•	 Most contraceptive methods can be used immediately after 
medical abortion.
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vi.  bringing mifepristone to new settings
The basic requirements for medical abortion service delivery include trained staff 
and the required medications (mifepristone and misoprostol). Staff should include 
skilled counselors and providers who are able to determine eligibility, confirm 
success, refer and/or provide women with emergency back-up care. 
A. Staff training
Staff at facilities offering medical abortion should be trained in each of the 
following:
•	 Protocols for medical abortion: Staff should be knowledgeable about 
mifepristone and misoprostol and the protocol being used in the clinic. 
•	 Counseling: Staff should receive comprehensive training on counseling for 
medical abortion (see Chapter V).
•	 Dating gestational age: Staff should be able to assess gestational duration 
by review of pertinent history, symptoms, and physical exam (see Chapter 
III, Section B). Since the effectiveness of medical abortion does not decrease 
dramatically with each day of increasing gestational length, it may not be 
necessary to date gestational age precisely. Lab tests to detect hormone levels 
and ultrasonography may aid in determining gestational age but are not 
requirements for service provision. 
Chapter themes 
•	 Staff training
•	 Service delivery components
•	 Dissemination of information 
•	 Medical abortion myths
•	 Confronting abortion stigma
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•	 Identifying rare pregnancy abnormalities: Staff should be knowledgeable about 
warning signs for rare pregnancy abnormalities such as ectopic pregnancies 
and hydatiform mole. Since women presenting for medical abortion usually 
seek care early in their pregnancies, providers have an opportunity to diagnose 
rare conditions early. Mifepristone and misoprostol have no effect on ectopic 
and molar pregnancies. 
•	 Determining success: Abortion status can be assessed at follow up by clinical 
history and exam (see Chapter IV, Section D). For example, if the clinician is 
able to detect an increase in uterine size compatible with additional weeks of 
fetal growth or if the woman is having prolonged bleeding problems, additional 
intervention is likely needed. 
•	 Values clarification: Discussion with staff about values may be useful, especially 
in instances where some of the staff members are ambivalent about providing 
abortion services.
Regardless of whether new providers are physicians or other health care providers, 
adequate medical abortion training will greatly improve their comfort and skill with 
the method. Recent studies have demonstrated that success and satisfaction with 
the method tends to increase as provider experience and skills increase. 
A basic training course should include the following elements:
•	 Mifepristone and misoprostol: Pharmacology and mechanism  
of action
•	 Eligibility and contraindications 
•	 Protocols for medical abortion 
•	 Diagnosing completed abortion, incomplete abortion and ongoing 
pregnancy 
•	 Managing side effects and adverse events 
•	 Ultrasound: Its advantages and disadvantages in various settings
•	 Counseling
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Experience has shown that use of case studies in training is quite helpful, especially 
when discussing management of side effects and diagnosis of abortion status. In 
addition, role plays and group activities have proven extremely effective means 
of training on eligibility and counseling. Several international organizations have 
developed training curricula for medical abortion (see Appendix E Additional 
Resources).
B. Service delivery components
Providers who currently offer family planning, pre-natal care or other reproductive 
health services can add medical abortion to their current services. In particular, 
surgical abortion providers can easily offer medical abortion services once they 
receive appropriate training. Studies have also shown that introduction of medical 
abortion is feasible in settings that previously had not provided abortion services. 
Providers can offer the method safely and effectively using existing referral 
mechanisms for management of miscarriage and without introducing a radical 
reconfiguration of services.26,77
Medications
•	 Mifepristone and misoprostol: Both drugs can be administered either at home 
or in the clinic. Regardless of where the drugs are administered, women should 
be carefully counseled on how and when to take each drug and on potential 
complications, expected and adverse effects, and management of these 
occurrences. 
Emergency care facilities/referral services
•	 Surgical termination: Since the method is not 100% effective, medical abortion 
providers should be able to perform or refer women for surgical completion, 
when needed.
•	 Emergency care: Women need to know where to go for emergency care. Most 
back-up care is similar to that needed by women following spontaneous 
abortion, and many communities have a health care facility already in place to 
provide such care. 
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Additional service delivery components
•	 Waiting area: If misoprostol is taken at the clinic, it is convenient to have an 
area where women can wait after taking the medication. A sufficient number of 
toilets should be nearby. Beds are rarely necessary, but comfortable chairs can 
be useful. Ideally, clinics provide space for a woman’s companion to stay with 
her during the abortion process. 
•	 Ultrasonography: As explained above, ultrasonography can be useful in 
determining gestational age, identifying pregnancy complications, and 
confirming abortion completion, if providers skilled in imaging and its 
interpretation are available. 
•	 Pain and anti-nausea medications: These products can be given to women 
in advance to be used as needed to help to ease side effects (see Chapter IV, 
Section C). 
•	 Anti-D globulin: While most guidelines recommend using anti-D globulin for 
Rh negative women with gestations of more than seven weeks, its use before 
seven weeks’ gestation is debated. It is possible that at this very early stage of 
pregnancy there is little, if any, opportunity for an exchange of blood between 
the woman and the fetus.78 More research is needed to determine exactly when 
such precautions are necessary. If the local standard of care indicates anti-D 
globulin for Rh negative women undergoing surgical or spontaneous abortion, 
this care also should be provided for women undergoing medical abortion until 
further evidence becomes available.
C. Dissemination of information
As with all new technologies, information dissemination is critical to building 
local and national support. International experience suggests that the following 
dissemination strategies have worked well:
•	 Promoting the method as a component of comprehensive reproductive health 
services. 
•	 Increasing women’s awareness and understanding of medical abortion through 
media and women’s organizations or groups. 
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•	 Communicating information among providers via medical journals.
•	 Introducing medical abortion at local, national and regional professional 
meetings, especially where the technology is relatively unknown and/or 
underutilized.
•	 Educating health workers at all levels, including physicians, mid-level providers, 
reception personnel, counselors and telephone operators. 
•	 Creating networks of service providers through which they can share their 
experiences. 
D. Medical abortion myths
It is important to respond to common myths regarding the method. The following 
are some common myths about medical abortion and factual evidence. 
Myth #1: Ultrasound is necessary for all medical abortion services. 
Many providers are concerned about offering medical abortion, especially in rural 
areas where ultrasound may not be available. While ultrasound is a useful tool 
both for gestational age dating and for identifying ectopic pregnancies, it is not 
irreplaceable. It is useful to identify a location where women can be referred for an 
ultrasound exam, if needed. 
Myth #2: Medical abortion is dangerous because it does not resolve ectopic 
pregnancies. 
Medical abortion is contraindicated for women with known ectopic pregnancies 
because mifepristone will not end an ectopic pregnancy. Medical abortion providers 
must be trained to diagnose ectopic pregnancy. Early contact between pregnant 
women seeking medical abortion and health care providers creates an opportunity 
to diagnose the condition sooner than would have been possible if the woman had 
chosen to continue her pregnancy.
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Myth #3: Only physicians can administer medical abortion.
Given the nature of medical abortion – women simply ingest two sets of pills 
– trained non-physician providers can be effective medical abortion providers. 
Provision of medical abortion by non-physician providers also may increase the 
pool of providers and build on the skills of staff such as nurse-midwives. Mid-
level clinicians play a crucial role in the provision of pregnancy-related care in 
many settings, particularly in rural or remote settings where physicians are scarce. 
Evidence suggests that various health care providers, including midwives and 
nurses specialized in pregnancy-related care, are either successfully engaged in 
the provision of medical abortion services or possess the skills needed to provide 
medical abortion with additional training.79
Myth #4: Medical abortion is not appropriate for women in rural areas.
If a health care facility offering medical abortion is not able to provide back-up care, 
such as surgical aspiration, the facility should be located in reasonable proximity to 
a center that can provide this care. For instance, rural hospitals and primary health 
care facilities can act as nodal points and provide back-up services to primary health 
care facilities in the geographic vicinity. This “hub and spoke” referral system is 
commonly used throughout much of the world for other types of health care delivery.
E. Confronting abortion stigma
While many countries, particularly in Sub-Saharan Africa and Latin America, 
have strict abortion laws, there are almost always limited circumstances in which 
abortion is permitted. If abortion is legally permitted, women should ideally be able 
to choose either surgical or medical abortion.
Below are suggestions for promoting the method in areas where abortion is highly 
stigmatized and restricted. 
•	 Emphasize that medical abortion is safe for women.
•	 Introduce the idea that medical abortion is similar to miscarriage.
•	 Some countries have had success launching medical abortion services by 
beginning to use misoprostol for treatment of incomplete abortion and 
miscarriage.
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Summary points:
•	 It is simple and straightforward to train providers to offer medical 
abortion in almost any setting.
•	 Medical abortion can be safely offered by many types of providers 
once they are trained.
•	 It is essential to disseminate information to women and to health 
care providers at all levels.
•	 Many of the barriers mentioned in relation to development of 
medical abortion services are myths.
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vii.  mifepristone and misoprostol for late first
 trimester abortion
Medical abortion with mifepristone and misoprostol is a standard of care 
throughout the first trimester in the United Kingdom and has been recommended 
by the Royal College of Obstetricians and Gynaecologists (RCOG).80 Research has 
documented success rates after 9 weeks’ LMP comparable to earlier gestations, 
with some modifications to the procedure. However, there are no studies that 
directly compare outcomes of earlier versus later procedures. Therefore, the 
information below is based on comparing observations across multiple studies.
A. Similarities to Early Medical Abortion: 
1. The method is successful in more than 90% of cases. The published 
experience with use of this method beyond 9 weeks’ LMP (nearly 3,000 
cases) demonstrates a cumulative efficacy of greater than 93%.81,82,83,84,85,86,87 
The largest case series, published by Hamoda, et al., demonstrated 
a decrease in efficacy non-significant in their series, with increasing 
gestational age: from 97.3% success in women 10 weeks’ LMP to 92.0% in 
women 13 weeks’ LMP.87
2. The time to expulsion is similar to time to expulsion in early medical 
abortion, between 4 and 5 hours on average, compared to between 3 and 4 
hours with earlier inductions.84,87 
3. Reported side effects are generally mild and transient. As in earlier 
inductions, after misoprostol administration, women report experiencing 
nausea, vomiting, diarrhea, fever, chills and headache. Most of these effects 
are transient and managed when necessary with anti-emetic and anti–
diarrheal medications.
4. When offered the option between medical and surgical abortion, women are 
highly satisfied with the procedure.83,88 
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B. Differences from Early Medical Abortion:
1. Procedure is usually performed in-clinic. Women presenting for early medical 
 abortion (through 9 weeks’ LMP) can take misoprostol, and subsequently  
 abort, at home. All of the studies and routine use of this treatment  
 beyond 9 weeks’ LMP involve either in-clinic or in-patient misoprostol  
 administration. Research is currently under way to determine whether these  
 later procedures could be provided outside the clinic setting; however, until  
 further investigations are complete only in-clinic or in-patient procedures  
 are recommended.
2. To have a successful procedure, women usually take multiple misoprostol 
 doses. Typical regimens for early abortion require one dose of misoprostol,  
 usually between 400 and 800 mcg, taken by one of several routes. For  
 women undergoing medical abortion beyond 9 weeks’ LMP, serial doses are 
 given at 3 to 4 hour intervals, until the woman has expelled the fetus.  
 Studies indicate that on average women administer two to three doses.  
 The regimen recommended by the RCOG is: 200 mg mifepristone followed  
 36 to 48 hours later by 800 mcg vaginally. After the initial misoprostol 
 dose, a maximum of four additional 400 mcg doses, orally or vaginally  
 (depending on whether the patient is bleeding), given every three hours  
 is recommended. 
3. Risk of bleeding requiring transfusion may be higher among women inducing 
 with mifepristone and misoprostol beyond 9 weeks. In the literature there are 
 8 reported transfusions out of approximately 3,000 procedures (2.8 per  
 1,000 procedures). This rate is higher than with inductions before 9 weeks’  
 LMP, which is about 1 per 2,000 procedures. A similar trend of increasing  
 bleeding complications is seen with later surgical procedures.89 
4. Women generally require more pain medication than with earlier inductions. 
 A review of over 4,000 medical abortion procedures from 5 through 22  
 weeks’ LMP demonstrated that analgesia requirement significantly 
increased with lower maternal age, higher gestation, longer induction-to-
abortion interval, and with increased misoprostol doses.90 At the same time, 
there is variation among clinics and providers as well as among cultures. 
Regardless, research indicates more women will require stronger analgesics 
during a procedure after 9 weeks’ LMP compared to earlier procedures.
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Summary points:
•	 Mifepristone-misoprostol medical abortion is safe and effective in 
the late first trimester (10-12 weeks’ LMP).
•	 Regimens for mifepristone-misoprostol medical abortion in the 
late first trimester use 200 mg mifepristone followed 36-48 hours 
later by misoprostol.
•	 Most studied regimens use multiple misoprostol doses 
and require women to remain in the clinic for misoprostol 
administration. Research on outpatient alternatives is ongoing.
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viii.  where there is no mifepristone
 
A. Methotrexate and misoprostol 
Methotrexate is a folic acid antagonist that interferes with DNA synthesis. When 
used as an abortifacient both alone and in combination with a prostaglandin, 
methotrexate can successfully end early intra-uterine and ectopic pregnancies.91 
For induced abortion, use of a complementary prostaglandin, such as misoprostol, 
induces uterine contractions, causing the expulsion to take place more quickly.92,93
Chapter themes 
•	 Methotrexate and misoprostol for medical abortion 
•	 Misoprostol-alone abortions
Mifepristone + 
misoprostol
•	 >95% effective 
•	 Acts rapidly
•	 Mifepristone can be costly 
•	 Not available worldwide
Methothrexate + 
misoprostol
•	 >90% effective •	 Acts slowly
•	 Potential to cause fetal 
malformations for ongoing 
pregnancies
Misoprostol alone •	 Mid-80’s% effective
•	 Least costly
•	 Widely available
•	 More side effects
•	 May be associated with fetal 
malformations for ongoing 
pregnancies
Regimen Advantages Disadvantages
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Regimens 
Methotrexate and misoprostol have been used for medical abortion up to 63 days’ 
LMP. The most commonly used regimen is 50 mg methotrexate orally, followed  
5 to 7 days later by 800 mcg misoprostol vaginally. The misoprostol dose is usually 
repeated after 24 hours if abortion has not occurred.
Methotrexate is currently available as both a solution and oral tablets. The solution 
can either be taken orally or injected intramuscularly. Intramuscular methotrexate is 
most commonly administered in a dose relative to the woman’s body surface area. 
Researchers have explored the possibility of administering the misoprostol 4, 5, or 6 
days after methotrexate and have found that each of these regimens is effective.94,95
Safety
Methotrexate is used for a number of indications other than medical abortion. The 
drug is not known to have any effect on future fertility or to increase the risk of 
abnormalities in future pregnancies.96,97,98 Pharmacokinetic studies indicate that the 
typical 50 mg oral dose is safe, as blood serum levels do not reach sustained toxic 
levels.99
 
Contraindications for methotrexate-misoprostol 
•	 Severe anemia 
•	 Known coagulopathy 
•	 Active liver or renal disease 
•	 Uncontrolled seizure disorder  
•	 Acute inflammatory bowel disease 
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It may be advisable for women who are taking folate-containing medications, 
including vitamins, to discontinue these medications for one week following 
methotrexate administration. Some clinicians advise against eating foods high in 
folate such as dark green leafy vegetables, broccoli, beans, brewers’ yeast, whole 
grains, wheat germ, oranges, and organ meats for two weeks after methotrexate, but 
there is no evidence that such precautions are necessary. Because methotrexate is 
excreted in breast milk, breast-feeding women who are able to provide alternative 
nutrition to their children should discard breast milk for 72 hours after taking 
methotrexate. 
Teratogenicity
Women should be advised about the possible teratogenic effects of methotrexate 
and misoprostol and counseled regarding the importance of surgical completion 
if the drugs do not successfully end the pregnancy. Anecdotal reports of a pattern 
of anomalies among infants born to women treated with methotrexate during 
pregnancy indicate that methotrexate is potentially teratogenic.100,101,102 Most 
reports of teratogenicity associated with methotrexate involve high doses used 
for chemotherapy. See Chapter II, Section C for information on misoprostol and 
teratogenicity. 
Efficacy 
The overall success rate of methotrexate-misoprostol medical abortion reported 
in the clinical trial literature varies between 88% to 97%103,104 (See Appendix A for 
success rates reported in clinical trials). Although these rates can be similar to those 
achieved with mifepristone, medical abortion with methotrexate takes longer to 
complete. 
As described in Chapter II, the efficacy of medical abortion is associated with the 
protocol used and provider experience; success rates increase when women wait 
longer to expel the products of conception before recourse to surgical evacuation. 
There is some evidence that methotrexate and misoprostol may be more effective at 
earlier gestational ages. However, the data are inconclusive and studies of abortion 
up to 63 days’ LMP report success rates above 90%.103,104 
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Acceptability 
Between 83% and 89% of participants in methotrexate medical abortion studies 
stated that they would choose the same method again.105,106 A study that compared 
the acceptability of mifepristone and methotrexate regimens found that acceptance 
was higher for mifepristone with significant differences in pain and waiting time 
between the two drugs.107
Side effects and complications
The side effects of methotrexate-misoprostol medical abortion are similar to those 
experienced with mifepristone-misoprostol regimens. A study comparing the side 
effects of mifepristone and methotrexate medical abortion regimens found that 
headaches were significantly more common after mifepristone and that diarrhea, 
fever, chills, and high “worst” pain scores were significantly more common after 
methotrexate.108 Management of side effects is similar to that recommended with 
mifepristone (see Chapter IV, Section C for recommendations). Differences in 
recommendations regarding failed or incomplete abortion and ectopic pregnancy 
are discussed below.
Failed or incomplete abortion
In most protocols, ongoing viable pregnancy has been defined as the presence 
of gestational cardiac activity on transvaginal ultrasonography two weeks after 
methotrexate administration. Intervention for a nonviable pregnancy is not 
necessary and expulsion will occur with time, on average 22 to 29 days after 
methotrexate. Current recommendations in the United States for medical abortion 
with methotrexate regimens suggest waiting at least 29 to 45 days before offering 
a surgical evacuation, though some women do not want to wait this long and may 
request a surgical intervention earlier.109
B. Misoprostol alone 
Misoprostol used alone for abortion is a promising alternative where mifepristone-
misoprostol regimens are not available. Studies have evaluated the efficacy of 
misoprostol used alone for both first and second trimester abortions. Given its wide 
availability, low price, and ease of use, women around the world have begun to use 
misoprostol without medical supervision as a means of abortion induction.
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Regimen
Most studies have assessed the efficacy of an 800 mcg dose of misoprostol 
repeated up to three times. A regimen of 800 mcg either vaginally every 3-12 hours 
or sublingually every three hours repeated up to three times has been shown to be 
effective (85%).110 
Safety
Millions of women have used misoprostol (both alone and in combination with 
mifepristone or methotrexate) for safe termination of pregnancy.
Uterine rupture
Misoprostol may increase the risk of uterine rupture, especially in later gestations 
and in women with a scarred uterus. The exact risk of uterine rupture with early 
medical abortion is unknown, but has not occurred in hundreds of thousands 
of recorded uses of mifepristone-misoprostol for early first trimester abortion. 
Anecdotal evidence exists of uterine rupture in women undergoing second trimester 
medical abortion using misoprostol (both alone111,112,113 and with mifepristone112). 
Teratogenicity
Although some studies conclude that there is no clear evidence of 
teratogenicity,114,115,116 others have found a connection between attempted unsafe 
abortion with misoprostol and congenital defects.117,118,119,120 Doctors and women 
need to be aware that failed termination in early pregnancy after exposure to 
misoprostol may lead to an abnormal fetus. Surgical termination is recommended if 
pregnancy is ongoing after exposure to misoprostol. 
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Efficacy
In areas where mifepristone is not available, use of misoprostol alone may be a 
good, safe alternative. Good regimen in the most recent studies have success rates 
in the mid-80’s percent range (See Appendix A for success rates reported in clinical 
trials). 
Acceptability 
Most studies do not explicitly investigate the acceptability of misoprostol alone, but 
available data suggest that acceptability is high. 
Side effects
As with other forms of medical abortion, the most commonly reported primary 
and secondary side effects are uterine cramping and pain, bleeding, and nausea. 
Management of side effects is the same as for mifepristone medical abortion (see 
Chapter IV, Section C).
Clandestine use of misoprostol
Self-administration of misoprostol to induce an abortion has been 
documented in settings both where abortion is widely available 
and highly restricted.121,122 This phenomenon has been observed in 
Brazil since the 1990’s and more recently in other Latin American 
countries. Use of misoprostol to induce abortion in this way appears 
to have decreased abortion-related mortality and morbidity.123 
Recent research conducted in the United States in three large urban 
centers showed that knowledge about misoprostol for abortion self-
induction is limited (about 4%).124
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Mode of administration 
Sublingual or vaginal administration of misoprostol are recommended. A large 
study conducted by the WHO found that when used vaginally the interval between 
doses could be either 3 or 12 hours. With sublingual, the 3-hour dosing led to more 
side effects but the 12-hour dosing interval was associated with lower efficacy.110 
Buccal administration is also being used for this purpose.
Telemedicine and mifepristone and misoprostol
Women on Web is a service that uses telemedicine to help women 
access mifepristone and misoprostol in countries with restrictive 
abortion laws and little to no safe abortion care. After an online 
consultation, women with an unwanted pregnancy of up to 9 weeks’ 
LMP consult with a physician. If there are no contraindications, 
mifepristone and misoprostol are mailed to the woman. 
http://www.womenonweb.org/
Summary points:
•	 Where mifepristone is not available, methotrexate and 
misoprostol are good medical abortion options.  
•	 Telemedicine may help to make medical abortion more available in 
settings where mifepristone and misoprostol are not available.
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iX.  looking forward 
This guidebook was made possible by the enormous progress in medical abortion 
technology over the last two decades. Finally, we have available a powerful tool 
that can be used widely to help solve a difficult and painful problem that is all too 
common in the lives of millions of women. The purpose of this guidebook is to 
show how the technology can be provided even where resources are scarce and 
medical services are not necessarily sophisticated.
The promise of medical abortion to ensure access to needed services, to increase 
the comfort and autonomy of women, and to improve health outcomes will not 
be fully realized until the technology is accessible in all places where women can 
choose to end unwanted pregnancies. Using the suggestions provided by this 
guidebook can help to advance the goal of making medical abortion a real choice for 
more women. 
At the time the contraceptive pill was developed, it was almost unimaginable that 
we would also be able to address the problem of abortion with medicines and 
avoid surgery. But indeed, we are really there. The method has been used by tens of 
millions of women in dozens of countries, and it is incontrovertibly safe, effective, 
acceptable, and feasible to introduce into services.
Nonetheless, we are not at the end of the line in improving the technology – and 
especially in re-thinking and re-designing aspects of services. We now know, for 
example, that fewer visits to the clinic are completely compatible with safety and 
efficacy of the method. The minimum visit mode of service delivery is also highly 
desirable to most women and to providers. One challenge, therefore, is to convince 
policymakers, regulatory agencies, health systems, and individual clinicians to 
provide medical abortion with the fewest possible visits. 
At the moment, we have a lot of positive experience with services that allow women 
to take the misoprostol at home and not return to the clinic for this purpose. 
Since it is the misoprostol, and not the mifepristone, that causes most of the 
uncomfortable side effects of the method, it is logical to explore the idea of allowing 
women to take the mifepristone at home as well. In the future, we can consider 
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mechanisms of allowing a woman to buy the mifepristone in the pharmacy 
(a situation that already exists in some places) and even to have it on hand should 
she need it at a later date.
Since many women feel perfectly well and tend to avoid re-visits to clinics after 
abortion, we need more research on ways to help eligible women safely skip return 
visits after completion of their medical abortions. We do know that women are 
very good at determining whether they might require additional care for medical 
complications, and with appropriate counseling, they should be able to self-refer 
back to facilities for this purpose. Documentation exists showing that women are 
unlikely to think that their abortion has succeeded when it is not yet complete and 
that they are more likely to believe that the pregnancy has not been ended when it 
already has terminated.125 In the future, there can be a place for inexpensive low-
sensitivity pregnancy tests to aid women in deciding when they may need care for a 
pregnancy that continues after medical abortion.
A great many services, in both more and less developed parts of the world, that 
provide medical abortion have discovered on their own that the method is simple 
to provide and that it can be provided very well by non-physicians. This insight 
is critical to making the method more accessible in low-resource environments. 
Another challenge for the future is to ensure that the message is widely known and 
understood by those who design services and develop norms for health services.
As for the science and technology itself, we look forward to a way to make the 
process of medical abortion even more comfortable for women, reducing what are 
now considered as the inevitable consequences of use of the method: bleeding 
and pain. For this goal, we will need to engage with the basic scientists to begin to 
explore alternative molecules and formulations. But why not? The past has been 
instructive and productive: the technology is here, and it works. The promise for the 
future is enormous, with dividends in the health and productivity of women all over 
the world. We look forward to being part of this exciting prospect.
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X.  appendices
Appendix A:  Efficacy of mifepristone and misoprostol, 
methotrexate and misoprostol and misoprostol alone for early 
medical abortion
Table 1 Efficacy of mifepristone and misoprostol for early 
 medical abortion
Reference N Gestational 
age
Dose 
mifepristone 
(mg)
First dose misoprostol 
(mcg)
Additional doses 
misoprostol (mcg)
Success 
(%)
Raghavan S, et al.51 240 ≤ 63 days 200 400 sublingual on 
day 2
99
 239 ≤ 63 days 200 400 oral on day 2 94
von Hertzen H, 
et al.55
529 ≤ 63 days 100 800 vaginal on day 2 93
534 ≤ 63 days 100 800 vaginal on day 3 91
531 ≤ 63 days 200 800 vaginal on day 2 94
532 ≤ 63 days 200 800 vaginal on day 3 93
Winikoff B, et al.53 421 ≤ 63 days 200 800 buccal on day 2 800 buccal on day 
8-14 if needed
96
426 ≤ 63 days 200 800 oral on day 2 800 oral on day 8-14 
if needed
91
Coyaji K, et al.46 147 ≤ 56 days 200 400 oral on day 3 86
 150 ≤ 56 days 200 400 oral on day 3 400 oral 3 hrs later 92
Guest J, et al.58 210 ≤ 63 days 200 800 vaginal on day 1 
(6 hrs after mife)
800 vaginal on day 
3 to 8 if needed
89
215 ≤ 63 days 200 800 vaginal on day 3 800 vaginal on day 
5 to 10 if needed
96
Creinin MD, et al.57 554 ≤ 63 days 200 800 vaginal on day 1 
(0-15 min after mife)
800 vaginal on day 
8 if needed
95
546 ≤ 63 days 200 800 vaginal on day 2 800 vaginal on day 
8 if needed
97
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Middleton T, et al.126 216 ≤ 56 days 200 800 buccal on day 2-3 95
213 ≤ 56 days 200 800 vaginal on day 2-3 93
Creinin MD, et al.56 525 ≤ 63 days 200 800 vaginal on day 1 
(6-8 hrs after mife)
800 vaginal on day 
8 if needed
96
531 ≤ 63 days 200 800 vaginal on day 2 800 vaginal on day 
8 if needed
98
Tang OS, et al.52 112 ≤ 63 days 200 800 vaginal on day 3  94
112 ≤ 63 days 200 800 sublingual on 
day 3
 98
von Hertzen H,  
et al.127
740 ≤ 63 days 200 800 oral on day 3 400 oral twice daily 
on days 4-10
92
741 ≤ 63 days 200 800 vaginal on day 3 400 oral twice daily 
on days 4-10
95
738 ≤ 63 days 200 800 vaginal on day 3  94
Schaff EA, et al.128 220 ≤ 63 days 200 400 oral on day 3 800 vaginal on day 
4-8 if needed
91
269 ≤ 63 days 200 800 oral on day 3 800 vaginal on day 
4-8 if needed
95
522 ≤ 63 days 200 800 vaginal on day 3 800 vaginal on day 
4-8 if needed
98
Bartley J, et al.129 453 ≤ 63 days 200 800 vaginal on day 3  99
Schaff et al.47 548 ≤ 63 days 200 400 oral on day 2 400 oral 2 hrs later, 
800 vaginal on day 
3-8 if needed
95
596 ≤ 63 days 200 800 vaginal on day 2 800 vaginal on day 
3-8 if needed
99
Schaff EA, et al.54 734 ≤ 56 days 200 800 vaginal on day 1  98
766 ≤ 56 days 200 800 vaginal on day 2  98
755 ≤ 56 days 200 800 vaginal on day 3  96
Table 1 (continued)
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Table 1  Efficacy of mifepristone and misoprostol for early  
 medical abortion (continued)
Schaff EA, et al.60 933 ≤ 56 days 200 800 vaginal on day 3  97
Spitz I, et al.6 827 ≤ 49 days 600 400 oral on day 3  92
678 50-56 days 600 400 oral on day 3  83
510 57-63 days 600 400 oral on day 3  77
Winikoff B, et al.14 1,373 ≤ 56 days 600 400 oral on day 3  84-95
Aubeny E, et al.130 1,108 ≤ 63 days 600 400 oral on day 3 200 oral 3 hrs later 
if needed
93
Baird DT, et al.131 386 ≤ 63 days 200 600 oral on day 3  95
El-Refaey H, et al.132 130 ≤ 63 days 600 800 oral on day 3  87
133 ≤ 63 days 600 800 vaginal on day 3  95
El-Refaey H, et al.133 150 ≤ 56 days 200 800 oral on day 3  93
Guo-wei S, et al.134 149 ≤ 49 days 150 600 oral on day 3  95
McKinley C, et al.135 110 ≤ 63 days 200 600 oral on day 3  94
110 ≤ 63 days 600 600 oral on day 3  94
Peyron R, et al.136 488 ≤ 49 days 600 400 oral on day 3  97
385 ≤ 49 days 600 400 oral on day 3 200 oral 4 hrs later 
if needed
99
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Table 2  Efficacy of methotrexate and misoprostol for early  
 medical abortion
Reference N Gestational 
age
Dose 
methotrexate 
(mg)
Dose misoprostol (mcg) Dosing 
Interval
Success 
(%)
Wiebe, et al.137 154 ≤ 49 days 50 mg/m2 IM 600 vaginal q 24 hrs x2 4-6 days 94
155 ≤ 49 days 50 mg/m2 IM 600 buccal q 24 hrs x2 4-6 days 90
Creinin, et al.138 26 ≤ 49 days 50 mg/m2 IM 800 vaginal 3-7 days 93
Borgatta, et al.139 1,973 ≤ 49 days 50 mg/m2 IM 800 vaginal q 24 hrs x2 if 
needed
5-7 days 84
Carbonell, et al.140 148 ≤ 56 days 25 mg oral 800 vaginal q 24 hrs if needed 7 days 91
Wiebe, et al.141 99 ≤ 49 days 50 mg/m2 IM None 5-6 days 83
256 ≤ 49 days 50 mg/m2 IM 800 vaginal 5-6 days 89
Carbonell, et al.94 300 ≤ 63 days 50 mg oral 800 vaginal, repeated at 48 
and 96 hrs if needed
3-5 days 91
Carbonell, et al.142 287 ≤ 63 days 50 mg/m2 IM 800 vaginal q 48 hrs x3 if 
needed (self-administered)
3-5 days 92-93
Wiebe, et al.143 289 ≤ 49 days 50 mg/m2 IM 750 vaginal 4-5 days 91
241 ≤ 49 days 50 mg/m2 IM 600 vaginal q 8 hrs x3 4-5 days 88
289 ≤ 49 days 50 mg/m2 IM 750 vaginal 4-5 days 91
226 ≤ 49 days 60 mg/m2 IM 750 vaginal 4-5 days 85
145 ≤ 49 days 50 mg/m2 IM 500 vaginal 4-5 days 93
144 ≤ 49 days 50 mg/m2 IM 750 vaginal 4-5 days 90
Creinin, et al.144 99 ≤ 49 days 75 mg IM 800 vaginal 5-6 days 95
202 ≤ 49 days 50 mg/m2 IM 800 vaginal 5-6 days 89
299 ≤ 49 days 50 mg/m2 
oral
800 vaginal 5-6 days 91
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Table 3 Efficacy of misoprostol alone for early medical abortion
Reference N Gestational 
age
First dose misoprostol 
(mcg) 
Additional doses misoprostol 
(mcg)
Success 
(%)
von Hertzen, et al.110 512 ≤ 63 days 800 sublingual q 3 hrs x3 84
509 ≤ 63 days 800 sublingual q 12 hrs x3 78
513 ≤ 63 days 800 vaginal q 3 hrs x3 85
512 ≤ 63 days 800 vaginal q 12 hrs x3 83
Aldrich, et al.103 2,444 ≤ 56 days 800 vaginal 800 vaginal if needed 77
Blanchard, et al.145 36 ≤ 56 days 400 oral q 3 hrs x4 39
24 ≤ 56 days 800 oral q 6 hrs x2 5
40 ≤ 56 days 600 vaginal 43
35 ≤ 56 days 800 oral q 3 hrs x2 46
25 ≤ 56 days 800 vaginal 60
51 ≤ 56 days 800 vaginal 800 vaginal at 24 hrs if needed 80
50 ≤ 56 days 800 vaginal q 24 hrs x2 66
Borgatta, et al.146 440 ≤ 56 days 800 vaginal q 24 hrs x2 91
Carbonell, et al.147 452 ≤ 63 days 800 vaginal q 8 hrs (self-administered) x3 91
Cheung, et al.148 50 ≤ 49 days 400 sublingual q 3 hrs x3 86
Singh, et al.149 150 ≤ 56 days 800 vaginal 400 vaginal q 3 hrs up to x3 85
Jain, et al.150 125 ≤ 56 days 800 vaginal q 24 hrs up to x3 88
Tang, et al.151 50 ≤ 83 days 600 sublingual q 3 hrs up to x5 86
Tang, et al.152 25 ≤ 83 days Varying doses 
sublingual
93
Zikopoulos, et al.153 160 ≤ 56 days 800 vaginal q 24 hrs up to x3 91
Carbonell, et al.154 300 42-63 days 1,000 vaginal q 24 hrs up to x3 93
Carbonell, et al.155 150 63-84 days 800 vaginal q 24 hrs up to x3 84
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Table 3 (continued)
Bugalho, et al.156 103 ≤ 42 days 800 vaginal 800 vaginal 7 days afterward if 
needed
92
Ngai, et al.157 80 ≤ 63 days 800 vaginal q 48 hrs up to x3 75
Velazco, et al.158 150 35-63 days 800 vaginal q 24 hrs up to x3 89
Carbonell, et al.159 180 64-91 days 800 vaginal q 12 hrs up to x3 85
Esteve, et al.160 720 35-63 days 800 vaginal q 24 hrs up to x3 89
Jain, et al.161 150 ≤ 56 days 800 vaginal q 24 hrs x2 + 800 vaginal 8 days 
afterward if needed
91
Jain, et al.162 100 ≤ 56 days 800 vaginal 800 vaginal 24 hrs afterward  
if needed
88
Ozeren, et al.163 36 ≤ 63 days 800 vaginal 800 vaginal on day 4 if needed 58
Tang, et al.164 20 ≤ 63 days 800 vaginal 400 vaginal q 3 hrs x4 70
Carbonell, et al.165 120 64-84 days 800 vaginal q 24 hrs up to x3 87
Carbonell, et al.166 175 ≤ 63 days 800 vaginal q 48 hrs up to x3 + 400-600 
vaginal if needed 
92
Carbonell, et al.167 141 ≤ 69 days 800 vaginal q 48 hrs up to x3 94
Bugalho, et al.168 101 35-77 days 200 vaginal q 12 hrs up to x4 46
133 35-77 days 400 vaginal q 12 hrs up to x4 66
Creinin, et al.169 61 ≤ 56 days 800 vaginal 800 vaginal 24 hrs afterward if 
needed
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Appendix B:  Counseling checklist for medical abortion
1. Discuss the differences between medical and surgical abortion:
2. Ask the woman to choose the method that she would like. 
3. If medical abortion is selected, confirm that the woman is eligible for this 
method.
4. Be sure that all women are:
•	 certain about the abortion decision
•	 at appropriate gestational age
•	 able to follow treatment protocol
•	 High success rate 
•	 Surgical intervention required in 
small percentage
•	 Avoids invasive procedures
•	 Avoids sedation and anesthesia
•	 Severe complications are rare
•	 Time to completion uncertain
•	 Involves multiple steps
•	 Woman has greater control
•	 High success rate
•	 Very small percentage may require 
re-evacuation
•	 Instruments inserted into the uterus
•	 Typically includes sedation with or 
without anesthesia
•	 Complications are rare. Infection from 
surgical instrumentation and injury to 
the genital tract can occur.
•	 Time to completion is predictable
•	 Involves a single step 
•	 Provider has greater control
Medical Abortion Surgical Abortion
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•	 willing to attend follow-up appointment, if needed
•	 willing to have surgical completion, if needed
•	 able to access emergency care
5. Explain the regimen: 
•	 Instruct how and when to administer misoprostol (if home use is 
chosen).
•	 Explain what to expect during the expulsion process.
6. Describe commonly experienced side effects:
•	 Vaginal bleeding comparable to or heavier than a normal heavy period
•	 Cramping
•	 Nausea, vomiting, and/or diarrhea
•	 Fatigue
•	 Each of these symptoms is normal and should not last a very long time
•	 Stock up on sanitary pads (or local equivalent)
7. Describe how to manage side effects:
•	 Analgesics
8. Explain when to contact the clinic:
•	 Severe pain not relieved by analgesics
•	 Soaking at least 2 extra large sanitary pads (or local equivalent) per hour 
for 2 consecutive hours
•	 Fever lasting 6 hours or more
9. Provide emergency contact information for the clinic.
10. Offer contraceptive information.
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11. Be sure that the woman leaves the clinic with the following:
•	 Misoprostol tablets (if home use regimen is chosen)
•	 Analgesia or a prescription for analgesia
•	 Instruction sheet that includes:
- Details on how and when to administer misoprostol (if home use 
regimen is chosen)
-  Description of side effects and how to manage them
-  Instructions for when to call the clinic
- Date and time of follow-up visit
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 Appendix C: Sample informed consent form  
The medical abortion procedure has been fully explained to me. I understand 
that I will be given mifepristone to take by mouth in the clinic and that I will 
need to take misoprostol from one to three days later. I understand that I will 
be asked to return to the clinic for a follow-up visit approximately two weeks 
after my first visit. I can also come to the clinic at any other time as well if 
I have any concerns or questions. I realize that I can request and receive a 
surgical abortion at any point in time. 
I understand that many women experience some side effects with medical 
abortion. I may feel some nausea and may vomit or have diarrhea. I realize 
that I will probably have abdominal pain or cramping, and bleeding. The 
bleeding may be heavier than I usually experience with my menses. I 
understand that all of these side effects are temporary. 
I also understand that the medical abortion regimen may fail to terminate 
my pregnancy. I have been told that this occurs in about five out of every one 
hundred cases. 
There are several reports of fetal abnormalities from women who have taken 
the combined regimen of mifepristone-misoprostol and then continued their 
pregnancies to term. Therefore, if the treatment fails, I realize that it is strongly 
recommended that I should have a surgical abortion. 
If I have a medical emergency, or any concerns about my medical abortion,  
I may call _________________ at telephone number: _________________. 
I, ____________________________________ (print name), would like to 
terminate my pregnancy with a medical abortion regimen. I have read and 
understand this informed consent form. All of my questions have been 
answered, and I have received the name and telephone number to call in case 
of emergency.
Signed: ____________________________________ Date: ___________
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Appendix D: Bellagio meeting participants
Dr. Paul Blumenthal
Professor of Gynecology and Obstetrics
Director, Family Planning Services and 
Research
Stanford University
300 Pasteur Drive, HH-333
Stanford, CA 94305-5317
Ms. Thembi Mazibuko 
Permanent Building
Woodley Street Entrance
Office Suite M6
Kimberley, South Africa 8300
Dr. Shelley Clark
McGill University
Associate Professor
Stephen Leacock Building, Room 713
855 Sherbrooke Street West
Montreal, Quebec, H3A 2T7
Dr. Vu Quy Nhan
Population Council 
2 Dang Dung Street 
Ba Dinh District 
Hanoi, Vietnam
Dr. Kurus J. Coyaji
K.E.M. Hospital
Rasta Peth
Pune, India 411011
Dr. André Ulmann
HRA – PHARMA
19, rue Frederick LeMaitre
75020 Paris, France
Dr. Charlotte Ellertson*
c/o Ibis Reproductive Health
2 Brattle Square
Cambridge, MA, U.S.A. 02138-3742
Dr. Beverly Winikoff
Gynuity Health Projects
15 East 26th St, 8th Floor
New York, NY, U.S.A. 10010
Dr. Christian Fiala
Gynmed Ambulatorium
Mariahilfer Gürtel 37
A-1150 Vienna, Austria
* deceased
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Appendix E:  Additional Resources 
Concept Foundation
www.medabon.info
Early Option Pill
www.earlyoptionpill.com
Ibis Reproductive Health - Medication Abortion Website
http://www.medicationabortion.com
International Consortium for Medical Abortion 
http://www.medicalabortionconsortium.org
Ipas 
http://www.ipas.org
Misoprostol Org 
http://www.misoprostol.org
National Abortion Federation (NAF) - Educational Resources
http://www.prochoice.org
Royal College of Obstetricians and Gynaecologists 
http://www.rcog.org.uk/files/rcog-corp/uploaded-files/NEBInducedAbortionfull.pdf
United States FDA - MIFEPREX™ (mifepristone) Label
http://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20687lbl.pdf
Women on Web 
http://www.womenonweb.org
World Health Organization - Safe Abortion: Technical and Policy Guidance for 
Health Systems
http://www.who.int/reproductivehealth/publications/unsafe_abor-
tion/9789241548434/en/index.html
World Health Organization - Frequently Asked Clinical Questions about Medical 
Abortion
http://www.who.int/reproductivehealth/publications/unsafe_abortion/9241594845/
en/index.html
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